Compare General Mills, Inc. (GIS) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Sanofi SA — how do they compare? General Mills, Inc. trades at $32.33 (market cap $17.43B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 5.5× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (7.49%). Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and Sanofi SA for 94 Days on average.
| GIS | SNY | |
|---|---|---|
Market Cap | $17.43B | $95.18B |
Volume | 16,554,362 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $52.34 |
52-Week Low | $31.67 | $39.51 |
Typical Hold Time | 106 Days | 94 Days |
Enterprise Value | $30.61B | $114.48B |
Dividend Yield | 7.49% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.29, up 1.64% today, showing mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 9.23 and P/S of 0.96. Recent Q2 2026 earnings beat expectations at $0.95 EPS versus $0.797 expected, though Q4 2025 missed. The company maintains dividend payments of $0.61 per share while facing profitability challenges with negative net income margin and ROE. Leadership transition is underway with Dana McNabb set to succeed Jeff Harmening as CEO.
Outlook remains cautious with analyst consensus at Hold (61%) and $36 price target. Key risks include declining revenue trends, margin pressure, and high debt levels at 45% of assets. The stock offers value appeal but requires successful execution of the $3B savings plan and turnaround strategy to drive sustainable growth amid competitive pressures.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
